Literature DB >> 17577004

Different ways to describe the benefits of risk-reducing treatments: a randomized trial.

Peder A Halvorsen1, Randi Selmer, Ivar Sønbø Kristiansen.   

Abstract

BACKGROUND: How physicians communicate the risks and benefits of medical care may influence patients' choices. Ways to communicate the benefits of risk-reducing drug therapies include the number needed to treat (NNT) to prevent adverse events, such as heart attacks or hip fractures, and gains in disease-free life expectancy or postponement of adverse events. Previous studies suggest that the magnitude of the NNT does not affect a layperson's decision about risk-reducing interventions, but postponement of an adverse event does affect such decisions.
OBJECTIVE: To examine laypersons' responses to scenarios that describe benefits as postponing an adverse event or the equivalent NNT.
DESIGN: Cross-sectional survey with random allocation to different scenarios.
SETTING: General community. PARTICIPANTS: Respondents to a population-based health study. INTERVENTION: The survey presented scenarios regarding a hypothetical drug therapy to reduce the risk for heart attacks (1754 respondents) or hip fractures (1000 respondents). The data sources for both scenarios were clinical trials. Respondents were randomly assigned to a scenario with 1 of 3 outcomes after 5 years of treatment. For the drug to prevent heart attacks, the outcomes were postponement by 2 months for all patients, postponement by 8 months for 1 of 4 patients, or an NNT of 13 patients to prevent 1 heart attack. For the drug to prevent hip fractures, the outcomes were postponement by 16 days for all patients, postponement by 16 months for 3 of 100 patients, or an NNT of 57 patients to prevent 1 fracture. MEASUREMENTS: Consent to receive the intervention and perceived ease of understanding the treatment effect.
RESULTS: The overall rate of response to the survey was 81%. In the heart attack scenarios, 93% of respondents who were presented with the NNT outcome consented to drug therapy, 82% who were presented with the outcome of large postponement for some patients consented to therapy, and 69% who were presented with the outcome of short postponement for all patients consented to therapy (chi-square, 89.6; P < 0.001). Corresponding consent rates for the hip fracture scenarios were 74%, 56%, and 34%, respectively (chi-square, 91.5, P < 0.001). Respondents who said that they understood the treatment effect were more likely to consent to therapy. LIMITATION: Decisions were based on hypothetical scenarios, not real clinical encounters.
CONCLUSIONS: Treatment effects expressed in terms of NNT yielded higher consent rates than did those expressed as equivalent postponements. This result suggests that the description of the anticipated outcome may influence the patient's willingness to accept a recommended intervention.

Entities:  

Mesh:

Year:  2007        PMID: 17577004     DOI: 10.7326/0003-4819-146-12-200706190-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

1.  Communicating risk to patients and the public.

Authors:  Gurudutt Naik; Haroon Ahmed; Adrian G K Edwards
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

2.  Evaluation of benefit-risk.

Authors:  Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Collaborating with youth to inform and develop tools for psychotropic decision making.

Authors:  Andrea Murphy; David Gardner; Stan Kutcher; Simon Davidson; Ian Manion
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-11

4.  Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Ivar Sønbø Kristiansen; Pia Veldt Larsen; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Dorte Ejg Jarbøl
Journal:  Br J Gen Pract       Date:  2014-04       Impact factor: 5.386

5.  The "number needed to treat" turns 20--and continues to be used and misused.

Authors:  Finlay A McAlister
Journal:  CMAJ       Date:  2008-09-09       Impact factor: 8.262

6.  Therapeutic decisions by number needed to treat and survival gains: a cross-sectional survey of lipid-lowering drug recommendations.

Authors:  Peder A Halvorsen; Torbjørn F Wisløff; Henrik Støvring; Olaf Aasland; Ivar Sønbø Kristiansen
Journal:  Br J Gen Pract       Date:  2011-08       Impact factor: 5.386

7.  Do Experts Understand Performance Measures? A Mixed-Methods Study of Infection Preventionists.

Authors:  Sushant Govindan; Beth Wallace; Theodore J Iwashyna; Vineet Chopra
Journal:  Infect Control Hosp Epidemiol       Date:  2017-12-05       Impact factor: 3.254

8.  Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  Morten Rix Hansen; Asbjørn Hróbjartsson; Anton Pottegård; Per Damkier; Kasper Søltoft Larsen; Kenneth Grønkjær Madsen; René dePont Christensen; Malene Elisa Lopez Kristensen; Palle Mark Christensen; Jesper Hallas
Journal:  J Gen Intern Med       Date:  2019-05-09       Impact factor: 5.128

9.  The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: implications for pay-for-performance programs.

Authors:  Christine A Sinsky; Valerie Foreman-Hoffman; Peter Cram
Journal:  J Gen Intern Med       Date:  2007-12-28       Impact factor: 5.128

10.  Development of life-expectancy tables for people with type 2 diabetes.

Authors:  Jose Leal; Alastair M Gray; Philip M Clarke
Journal:  Eur Heart J       Date:  2008-12-24       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.